Received Jul 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | EB499 | — |
Boostrix Administration after temperature excursion; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a 11-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number EB499, expiry date 26-AUG-2027) for prophylaxis. On 20-JUN-2025 09:30, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: Boostrix Administration after temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-JUN-2025 Pharmacist called to verify if doses of vaccines that had been exposed to low temperatures should be repeated. Boostrix was administered after temperature excursion which led to Incorrect storage of drug.; Sender's Comments: US-GSK-US2025079387:same reporter /different patient US-GSK-US2025079386:same reporter /different patient US-GSK-US2025079384:same reporter /different patient US-GSK-US2025079385:same reporter /different patient US-GSK-US2025079382:same reporter /different patient US-GSK-US2025079374:same reporter /different patient US-GSK-US2025079376:same reporter /different patient US-GSK-US2025079375:same reporter /different patient US-GSK-US2025079378:same reporter /different patient